Metraipolis › archive › dc_f096fa697d9c

Targeting BCL11B-mediated JAK2/STAT3 activation: A novel therapeutic strategy for Parkinson's disease — Europe PMC PMID:42898226

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42898226
DOI
10.1016/j.isci.2026.117833
License (as archived)
solo-consultazione
Archived
2026-11-01T04:42:03.260Z
SHA-256 of the archived text
4080260ac4df4f43f08fec554e334526500d3331311ea7200a1f3c2d9dd44175
Stable URL of this page
https://metraipolis.com/documento/dc_f096fa697d9c

How to cite

Targeting BCL11B-mediated JAK2/STAT3 activation: A novel therapeutic strategy for Parkinson's disease — Europe PMC PMID:42898226 — Europe PMC (en), https://europepmc.org/article/MED/42898226 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f096fa697d9c (Metraipolis archive dc_f096fa697d9c, sha256 4080260ac4df4f43f08fec554e334526500d3331311ea7200a1f3c2d9dd44175)
BibTeX
@misc{dcf096fa697d9c,
  title = {Targeting BCL11B-mediated JAK2/STAT3 activation: A novel therapeutic strategy for Parkinson's disease — Europe PMC PMID:42898226},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42898226},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f096fa697d9c; sha256 4080260ac4df4f43f08fec554e334526500d3331311ea7200a1f3c2d9dd44175},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42898226. Agents can read the archived copy with the MCP tool read_document.